History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Journal of psychoactive drugs January 1, 2014 Amy Emerson, Linnae Ponté, Lisa Jerome et al. 64 citations
The Multidisciplinary Association for Psychedelic Studies (MAPS) was founded in 1986 as a nonprofit psychedelic pharmaceutical company in response to the 1985 scheduling of MDMA. MAPS developed the first double-blind, placebo-controlled trial of MDMA-assisted psychotherapy for PTSD and plans for FDA prescription approval in 2021. Its research expanded to include LSD-assisted psychotherapy for anxiety from life-threatening illness, observational studies of ibogaine for addiction, and MDMA for social anxiety in people with autism. MAPS' harm-reduction efforts aim to avoid backlash and build a post-prohibition world by helping non-medical users transform difficult psychedelic experiences into growth opportunities.